NEW YORK (GenomeWeb) – In competing notes to investors today, analysts at Evercore ISI and Piper Jaffray have issued new opinions on Hologic, with Evercore downgrading the company to Hold from Buy, and Piper Jaffray upgrading it to Overweight from Neutral.

The banks also changed their price targets for Hologic. Evercore lowered its target to $42 while Piper Jaffray raised its to $48.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.